NCT02170038View on ClinicalTrials.gov

Clinical Study Investigating the Conversion of the Contraceptive Compound Norethisterone Within the Body Towards the Contraceptive Compound Ethinylestradiol

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

March 31, 2015

Conditions
Pharmacokinetics
Interventions
DRUG

Microgynon

Subjects will receive 21 daily oral doses of Microgynon tablets containing 0.15 mg levonorgestrel und 0.03 mg ethinylestradiol.

DRUG

Noristerat(BAY86-6308)

Subjects will receive one intramuscular dose of Noristerat (oily solution for intramuscular injection) containing 200 mg norethisterone enantate.

Trial Locations (1)

13353

Berlin

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY